entertainment -WSS

entertainment

author：entertainment 2025-09-27 12:54:41 - browse：2968

Adam's take main illustration — Molly Ferguson/STAT

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam.

Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studies is the ethically correct thing to do.The FDA has the power to place clinical holds on experimental drugs when there’s evidence of an unacceptable safety risk to study participants. Simufilam doesn’t appear to be toxic. It’s not causing dangerous side effects. But study participants can also be harmed when they volunteer for a clinical trial based on false or misleading information about a drug’s potential efficacy.

The CUNY committee charged with investigating Cassava’s principal scientific collaborator, the neuroscientist Hoau-Yan Wang, could not definitively prove that Wang faked simufilam data, but that’s only because he refused to turn over original data and primary research records that the committee had requested to examine. Wang also claimed that boxes of research records relevant to the investigation were thrown away. The investigative report was first made public last week in the journal Science.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Eli Lilly’s Zepbound improved liver scarring in mid

WSS

FTC loses bid to block Novant's North Carolina hospital merger

An outdated Medicare rule harms dementia patients with anxiety

The most pressing bird flu mysteries scientists want answered

Illumina board agrees to spin off Grail, as divestment plans proceed

Stopping antidepressants leads to symptoms for 1 in 6 patients

BD to buy Edwards patient monitoring unit for $4.2 billion

explore

entertainment

hotspot

At least 13 dead in Texas as scorching temps continue

BD to buy Edwards patient monitoring unit for $4.2 billion

Sports medicine is finally prioritizing gender equality

Senators tussle over abortion against the backdrop of a presidential campaign

After affirmative action ruling, medical educators look to 'holistic review'

Stopping antidepressants leads to symptoms for 1 in 6 patients

The cancer drug shortage isn’t new — and neither are the solutions

The most pressing bird flu mysteries scientists want answered

The high cost of giving birth even with insurance

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Wikipedia

Elevance PBM president out as customers face prescription chaos

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

STAT wants to know your pick for a great summer read or listen

The most pressing bird flu mysteries scientists want answered

FDA approves Moderna’s RSV vaccine, its second licensed product

Sutter Health’s antitrust win overturned by appeals court

hotspot

entertainment

knowledge

leisure time